Detalles de la búsqueda
1.
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
PLoS Med
; 17(10): e1003348, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33125391
2.
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
PLoS One
; 12(2): e0170395, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28170401
3.
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.
J Immunol Methods
; 430: 1-9, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26779831
4.
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
PLoS One
; 11(11): e0162752, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27806057
5.
Development of an ultra-sensitive single molecule counting assay for the detection of interleukin-13 as a marker for asthmatic severity.
J Immunol Methods
; 426: 82-5, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26284890
6.
Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody.
J Immunol Methods
; 375(1-2): 258-63, 2012 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-22001556
Resultados
1 -
6
de 6
1
Próxima >
>>